Success Metrics

Clinical Success Rate
92.3%

Based on 12 completed trials

Completion Rate
92%(12/13)
Active Trials
0(0%)
Results Posted
50%(6 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
4
31%
Ph phase_1
6
46%
Ph phase_2
2
15%

Phase Distribution

6

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
6(50.0%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
4(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

12 of 13 finished

Non-Completion Rate

7.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(12)
Terminated(1)

Detailed Status

Completed12
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (50.0%)
Phase 22 (16.7%)
Phase 34 (33.3%)

Trials by Status

completed1292%
terminated18%

Recent Activity

0 active trials
Showing 5 of 13
completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

NCT01862367
completedphase_3

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

NCT00978380
completedphase_2

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

NCT00914589
completedphase_3

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

NCT01230021
completedphase_3

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

NCT00713648
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01862367

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

Completed
NCT00978380Phase 3

Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725

Completed
NCT00914589Phase 2

Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery

Completed
NCT01230021Phase 3

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

Completed
NCT00713648Phase 3

Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency

Completed
NCT01847989Phase 1

Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers

Completed
NCT02239146Phase 1

Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

Completed
NCT00056589Phase 1

Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

Completed
NCT01082406Phase 1

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Completed
NCT01253811Phase 3

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

Completed
NCT01706159Phase 2

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Terminated
NCT01153997Phase 1

Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers

Completed
NCT01848002Phase 1

Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13